Login / Signup

Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea.

Nicole E Scangarella-OmanMohammad HossainCaroline R PerryCourtney TiffanyMarcy PowellBrandon SwiftEtienne F Dumont
Published in: Sexually transmitted infections (2022)
isolates, reduce resistance potential and limit plasma concentrations of potential safety concern, compared with higher doses.
Keyphrases
  • phase iii
  • open label
  • clinical trial
  • human health
  • signaling pathway
  • men who have sex with men
  • phase ii
  • risk assessment
  • randomized controlled trial
  • placebo controlled